RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31

Transcode Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.70+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.63M
P/E (TTM): –
Dividend yield: –

Transcode Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	13	9.71	12	10	2.75	0.28
General & Administrative	5.77	5.95	7.15	8.40	3.40	0.44
Operating Expenses	28	16	19	19	6.15	0.73
Operating Income	-28	-16	-19	-19	-6.15	-0.73
Interest Expense	0.01	0.03	0.06	0.03	0.10	0.39
Interest & Investment Income	0.08	0.00	0.01	0.02	0.00	0.00
Other Non-Operating Income	-6.45	-1.09	0.87	1.07	-0.69	-1.62
Asset Impairment Charges	0	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0.00	–	–	0.00	–
Pretax Income	-34	-17	–	–	–	–
Income Tax Expense	0.23	0	0	0	0.05	0
Net Income incl. Noncontrolling Interests	-35	-17	-19	-18	-6.84	-2.34
Net Income	-35	-17	-19	-18	-6.84	-2.34
Net Income to Common	-36	-17	-19	–	–	–
EPS (Basic)(per share)	-52.59	-1,336.63	-3,419.01	-1,082.79	-16.20	-10.20
EPS (Diluted)(per share)	-52.59	-1,336.63	-3,419.01	-1,082.79	-16.20	-10.20
Shares Outstanding (Basic, Weighted)(shares)	0.69	0.01	0.01	0.02	0.42	0.23
Shares Outstanding (Diluted, Weighted)(shares)	0.69	0.01	0.01	0.02	0.42	0.23
EBITDA	-28	-16	-19	-19	-6.11	-0.73

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -833.5%

Financial strength

Current ratio: 1.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 155.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –